As a fully integrated development company, Enteris BioPharma has utilized the 505(b)(2) pathway to develop an internal clinical pipeline to address significant unmet medical needs.
Enteris BioPharma’s internal product pipeline consists of novel re-formulations of marketed drugs, enabling new treatment opportunities for which a more convenient drug delivery option does not exist. Enteris has successfully adapted Peptelligence to develop oral products of drugs that were previously only available as injectable, and remains a pioneer in developing other non-invasive, patient-compliant drug products.
With a strong regulatory strategy, proven track record of enabling oral drug delivery, and robust CMC capabilities, Enteris BioPharma is well equipped to lead oral drug development from bench to market.
CONTACT US
